Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection

Andrew I. Flyak, Xiaoli Shen, Charles D. Murin, Hannah L. Turner, Joshua A. David, Marnie L. Fusco, Rebecca Lampley, Nurgun Kose, Philipp A. Ilinykh, Natalia Kuzmina, Andre Branchizio, Hannah King, Leland Brown, Christopher Bryan, Edgar Davidson, Benjamin J. Doranz, James C. Slaughter, Gopal Sapparapu, Curtis Klages, Thomas G. KsiazekErica Ollmann Saphire, Andrew B. Ward, Alexander Bukreyev, James E. Crowe

Research output: Contribution to journalArticlepeer-review

110 Scopus citations


Summary Recent studies have suggested that antibody-mediated protection against the Ebolaviruses may be achievable, but little is known about whether or not antibodies can confer cross-reactive protection against viruses belonging to diverse Ebolavirus species, such as Ebola virus (EBOV), Sudan virus (SUDV), and Bundibugyo virus (BDBV). We isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycoprotein (GP) using peripheral blood B cells from survivors of the 2007 BDBV outbreak in Uganda. We determined that a large proportion of mAbs with potent neutralizing activity against BDBV bind to the glycan cap and recognize diverse epitopes within this major antigenic site. We identified several glycan cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb that completely protected Guinea pigs from the lethal challenge with heterologous EBOV. Our results provide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus infections.

Original languageEnglish (US)
Pages (from-to)392-405
Number of pages14
Issue number3
StatePublished - Jan 28 2016

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection'. Together they form a unique fingerprint.

Cite this